Sino Biopharmaceutical Ltd (1177) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Business description - A detailed description of the company’s operations and business divisions.
Corporate strategy - Analyst’s summarization of the company’s business strategy.
SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
Company history - Progression of key events associated with the company.
Major products and services - A list of major products, services and brands of the company.
Key competitors - A list of key competitors to the company.
Key employees - A list of the key executives of the company.
Executive biographies - A brief summary of the executives’ employment history.
Key operational heads - A list of personnel heading key departments/functions.
Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Sino Biopharmaceutical Ltd (Sino Biopharma), a subsidiary of Charoen Pokphand Group Co Ltd, is a research-oriented pharmaceutical company that develops, manufactures, and markets medicines, biopharmaceuticals, and Chinese medicines. It offers medicines for the treatment of hepatitis, cardio-cerebral diseases, cancer, orthopedic conditions, infectious diseases, and respiratory and digestive diseases, among others. The company offers products in various dosage forms including large-volume injections, PVC-free soft bags for intravenous injections, small-volume injections, powdered medicines, granulated medicines, capsules and tablets. It works in partnership with several domestic and foreign pharmaceutical companies to advance the development of its products. Sino Biopharma is headquartered in Wanchai, Hong Kong.
Sino Biopharmaceutical Ltd Key Recent Developments
Aug 25, 2025: Voluntary Announcement Data From Four Studies of “TQC3721 (PDE3/4 Inhibitor)”, “TQC2731 (Tslp Monoclonal Antibody)” and “TQC3403 (Umeclidinium Bromide and Vilanterol Trifenatate Powder for Inhalation)” Presented at ERs 2025
Aug 18, 2025: Sino Biopharmaceutical Announces Interim Results for Six Months Ended June 30, 2025
Jun 13, 2025: Sino Biopharmaceutical : Latest Progress of Innovation-Driven Development of the Group
Apr 25, 2025: Sino Biopharmaceutical Voluntary Announcement : 45 Research Results Will Be Presented at 2025 ASCO Annual Meeting (Including 12 Oral Sessions)
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Section 1 - About the Company
Sino Biopharmaceutical Ltd - Key Facts
Sino Biopharmaceutical Ltd - Key Employees
Sino Biopharmaceutical Ltd - Key Employee Biographies
Sino Biopharmaceutical Ltd - Major Products and Services
Sino Biopharmaceutical Ltd - History
Sino Biopharmaceutical Ltd - Company Statement
Sino Biopharmaceutical Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 - Company Analysis
Company Overview
Sino Biopharmaceutical Ltd - Business Description
Business Segment: Investment
Overview
Performance
Business Segment: Modernised Chinese Medicines and Chemical Medicines
Overview
Performance
Business Segment: Others
Overview
Performance
R&D Overview
Sino Biopharmaceutical Ltd - Corporate Strategy
Sino Biopharmaceutical Ltd - SWOT Analysis
SWOT Analysis - Overview
Sino Biopharmaceutical Ltd - Strengths
Sino Biopharmaceutical Ltd - Weaknesses
Sino Biopharmaceutical Ltd - Opportunities
Sino Biopharmaceutical Ltd - Threats
Sino Biopharmaceutical Ltd - Key Competitors
Section 3 - Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
Sino Biopharmaceutical Ltd, Pharmaceuticals & Healthcare, Deals by Year, 2019 to YTD 2025
Sino Biopharmaceutical Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
Sino Biopharmaceutical Ltd, Recent Deals Summary
Section 5 - Company’s Recent Developments
Aug 25, 2025: Voluntary Announcement Data From Four Studies of “TQC3721 (PDE3/4 Inhibitor)”, “TQC2731 (Tslp Monoclonal Antibody)” and “TQC3403 (Umeclidinium Bromide and Vilanterol Trifenatate Powder for Inhalation)” Presented at ERs 2025
Aug 18, 2025: Sino Biopharmaceutical Announces Interim Results for Six Months Ended June 30, 2025
Jun 13, 2025: Sino Biopharmaceutical : Latest Progress of Innovation-Driven Development of the Group
Apr 25, 2025: Sino Biopharmaceutical Voluntary Announcement : 45 Research Results Will Be Presented at 2025 ASCO Annual Meeting (Including 12 Oral Sessions)
Mar 20, 2025: Sino Biopharmaceutical Announces Annual Results for Year Ended December 31, 2024
Dec 30, 2024: Wuxi Biologics Signs Service Agreement With Sino Biopharm
Nov 27, 2024: Sino Biopharmaceutical : Voluntary Announcement Approval for Marketing of Benmelstobart in Combination With Anlotinib for the Treatment for Endometrial Cancer
Oct 30, 2024: Sino Biopharmaceutical : 2024 Third Quarter Update
Aug 14, 2024: Sino Biopharmaceutical Reports Interim Results for Six Months Ended June 30, 2024
Apr 29, 2024: Voluntary Announcement 52 Research Results Will Be Presented At 2024 Asco Annual Meeting
Section 6 - Appendix
Methodology
Ratio Definitions
About the Analyst
Contact the Publisher
Disclaimer
List of Tables
Sino Biopharmaceutical Ltd, Key Facts
Sino Biopharmaceutical Ltd, Key Employees
Sino Biopharmaceutical Ltd, Key Employee Biographies
Sino Biopharmaceutical Ltd, Major Products and Services
Sino Biopharmaceutical Ltd, History
Sino Biopharmaceutical Ltd, Other Locations
Sino Biopharmaceutical Ltd, Subsidiaries
Sino Biopharmaceutical Ltd, Key Competitors
Sino Biopharmaceutical Ltd, Ratios based on current share price
Sino Biopharmaceutical Ltd, Annual Ratios
Sino Biopharmaceutical Ltd, Interim Ratios
Sino Biopharmaceutical Ltd, Pharmaceuticals & Healthcare, Deals by Year, 2019 to YTD 2025
Sino Biopharmaceutical Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
Sino Biopharmaceutical Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Sino Biopharmaceutical Ltd, Performance Chart (2020-2024)
Sino Biopharmaceutical Ltd, Ratio Charts
Sino Biopharmaceutical Ltd, Pharmaceuticals & Healthcare, Deals by Year, 2019 to YTD 2025
Sino Biopharmaceutical Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2019 to YTD 2025
This product is a company SWOT Analysis. Each license type allows a set number of users to access the report. Please select an option from the list below. This product is a company SWOT Analysis. This is a single user license, allowing one user access to the product. The product is a PDF. This product is a company SWOT Analysis. This is a site license, allowing all users within a given geographical location of your organization access to the product. The product is a PDF.
The sample excerpt is provided to help you make an informed purchasing decision. It is not intended to serve as free content or replace a full report. To ensure the sample aligns with your specific needs, our team will contact you to better understand your requirements.
An error occurred while sending the message. Should this issue persist, email us at help@researchandmarkets.net
This report can be tailored to focus on a specific country, region, continent, or provide global coverage. Please indicate your regions of interest and share any additional questions you may have. Our team strives to respond to all inquiries within the same business day.
An error occurred while sending the message. Should this issue persist, email us at help@researchandmarkets.net